Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy.
10.3341/kjo.2012.26.3.157
- Author:
Han Joo CHO
1
;
Ji Seon BAEK
;
Dong Won LEE
;
Chul Gu KIM
;
Jong Woo KIM
Author Information
1. Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. -medical-@hanmail.net
- Publication Type:Original Article ; Clinical Trial ; Comparative Study
- Keywords:
Bevacizumab;
Polypoidal choroidal vasculopathy;
Ranibizumab
- MeSH:
Angiogenesis Inhibitors/administration & dosage;
Antibodies, Monoclonal, Humanized/*administration & dosage;
Choroid/*blood supply;
Choroid Diseases/diagnosis/*drug therapy/physiopathology;
Dose-Response Relationship, Drug;
Female;
Fluorescein Angiography;
Follow-Up Studies;
Fovea Centralis/pathology;
Fundus Oculi;
Humans;
Intravitreal Injections;
Male;
Middle Aged;
Peripheral Vascular Diseases/diagnosis/*drug therapy/physiopathology;
Retrospective Studies;
Time Factors;
Tomography, Optical Coherence;
Treatment Outcome;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity
- From:Korean Journal of Ophthalmology
2012;26(3):157-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To compare the effectiveness of intravitreal injections of bevacizumab and ranibizumab in patients with treatment-naive polypoidal choroidal vasculopathy (PCV). METHODS: Records from 106 consecutive patients who received intraviteral bevacizumab (n = 58, 1.25 mg) or ranibizumab (n = 52, 0.5 mg) for treatment of PCV were retrospectively reviewed. After three initial monthly loading injections, injection was performed as needed. The main outcome measures included best-corrected visual acuity (BCVA), foveal central thickness (FCT) as assessed by spectral domain optical coherence tomography, and the changes in polypoidal lesions based on an indocyanine green angiography. RESULTS: The average number of injections was 3.31 +/- 1.25 in the bevacizumab group and 3.44 +/- 0.92 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline to 6 months after injection improved by 0.17 in the bevacizumab group (p = 0.03) and by 0.19 in the ranibizumab group (p = 0.01). Average FCT decreased from 322 +/- 62.48 microm to 274 +/- 40.77 microm in the bevacizumab group (p = 0.02) and from 338 +/- 50.79 microm to 286 +/- 36.93 microm in the ranibizumab group (p = 0.02). Polyp regression rate was 20.7% (12 of 58 eyes) in the bevacizumab group and 21.2% (11 of 52 eyes) in the ranibizumab group. There was no statistically significant difference between groups in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups. CONCLUSIONS: Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilizing of visual acuity, macular edema, and regression of polypoidal complex in PCV eyes over the short term.
